“…However, the antibodies induced by AMA-1 recognize either conserved or allele-specific epitopes of AMA-1, resulting in limited protection against distinct alleles [ 15 , 16 , 17 ]. Despite the less variable genetic diversity of AMA-1 compared to other vaccine candidate antigens, such as circumsporozoite protein (CSP), Duffy-binding protein (DBP), and merozoite surface protein-1 (MSP-1), in the global population, it manifests irrefutable polymorphism [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Genetic polymorphism of AMA-1 in global Plasmodium field isolates, and the resulting variants in different geographic areas, are major hurdles in the development of a global malaria vaccine based on this antigen.…”